PMID- 33216054
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1538-067X (Electronic)
IS  - 1092-1095 (Linking)
VI  - 24
IP  - 6
DP  - 2020 Dec 1
TI  - PI3K Inhibitors and Adverse Events: Optimizing Patient Care for the Treatment of 
      Advanced Breast Cancer.
PG  - 673-680
LID - 10.1188/20.CJON.673-680 [doi]
AB  - BACKGROUND: Excessive activation of the PI3K pathway has been associated with 
      malignant transformation and resistance to treatment in various cancer types. 
      Various PI3K inhibitors have been evaluated in phase 3 clinical trials; however, 
      most have been associated with modest clinical improvement and poor tolerability. 
      The safety profile of PI3K inhibitors poses new challenges in treatment 
      monitoring and management of common adverse events (AEs). OBJECTIVES: The purpose 
      of this article is to provide an overview of AEs associated with PI3K inhibitors, 
      with a focus on alpelisib, as well as guidance on the prevention and management 
      of AEs. METHODS: The literature and results from phase 3 trials evaluating the 
      efficacy and safety of endocrine therapy plus PI3K inhibitors in patients with 
      advanced breast cancer were reviewed. FINDINGS: AEs associated with PI3K 
      inhibitors include hyperglycemia, diarrhea, nausea, rash, and decreased appetite. 
      Prevention strategies are recommended to avoid the development or decrease the 
      severity of these AEs. Patient education and multidisciplinary care are necessary 
      for the optimal care of these patients.
FAU - Donahue, Sarah
AU  - Donahue S
AD  - University of California San Francisco Helen Diller Family Comprehensive Cancer 
      Center.
FAU - Santos Fulgencio, Gretchen
AU  - Santos Fulgencio G
AD  - University of California San Francisco Medical Center.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin J Oncol Nurs
JT  - Clinical journal of oncology nursing
JID - 9705336
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - *Breast Neoplasms/drug therapy
MH  - Female
MH  - Humans
MH  - Patient Care
MH  - *Phosphatidylinositol 3-Kinases/therapeutic use
MH  - Phosphoinositide-3 Kinase Inhibitors
OTO - NOTNLM
OT  - PI3K inhibitors
OT  - advanced breast cancer
OT  - adverse events
OT  - endocrine therapy
EDAT- 2020/11/21 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/11/20 12:13
PHST- 2020/11/20 12:13 [entrez]
PHST- 2020/11/21 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
AID - 10.1188/20.CJON.673-680 [doi]
PST - ppublish
SO  - Clin J Oncol Nurs. 2020 Dec 1;24(6):673-680. doi: 10.1188/20.CJON.673-680.